RPRX
Royalty Pharma plc
$61.41
+0.56
(+0.92%)
Mkt Cap
27.22B
Volume
3,773,772
52W Range
34.081-62.455
Sector
Healthcare
Beta
0.42
EPS (TTM)
2.41 USD
P/E Ratio
25.48
Revenue (TTM)
2.54B USD
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+12.7%
AlphaVal · Fair Value
What we estimate one share is worth
$78.64
Fair Value
moderate signal
21.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C
Stable Earnings Power
52.2 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| EPS | 2.33 | 1.92 | 3.41 | 0.10 | 1.49 | 1.28 | 6.63 | 3.89 | 3.42 | 0.93 | 0.96 |
| Free Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| FCF / Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 | 5.24 | 4.71 | 4.57 | 4.00 | N/A | N/A |
| Operating CF | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| Total Assets | 19.62B | 18.22B | 16.38B | 16.81B | 17.52B | 16.02B | 12.45B | 11.37B | 11.37B | 10.48B | 10.82B |
| Total Debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | 6.52B | 6.80B | 5.90B | 5.99B |
| Cash & Equiv | 618.70M | 929.03M | 477.01M | 1.71B | 1.54B | 1.01B | 246.20M | 1.92B | 1.38B | 1.67B | 1.72B |
| Book Value | 6.48B | 6.95B | 6.53B | 5.63B | 5.78B | 4.82B | 6.11B | 4.49B | 4.46B | 4.45B | 4.68B |
| Return on Equity | 0.12 | 0.12 | 0.17 | 0.01 | 0.11 | 0.20 | 0.38 | 0.31 | 0.27 | 0.13 | 0.12 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.14M | 630.58M | 621.99M | 609.29M | 578.66M | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M | 596.07M | 536.31M |
| Net Income | 17.88M | 295.00M | 214.21M | 288.22M | 30.18M | 238.35M | 208.21M | 543.99M | 102.00M | 4.78M | 494.34M | 72.11M |
| EPS | 0.04 | 0.68 | 0.64 | 1.05 | 0.09 | 0.55 | 0.47 | 1.22 | 0.23 | 0.01 | 1.48 | 0.21 |
| Free Cash Flow | 686.15M | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
| FCF / Share | 1.54 | 1.76 | 1.92 | 1.63 | 0.86 | 1.37 | 1.66 | 1.58 | 1.46 | 1.48 | 1.72 | 1.28 |
| Operating CF | 686.15M | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
| Total Assets | 19.82B | 19.82B | 19.62B | 19.35B | 18.32B | 17.61B | 18.22B | 18.04B | 17.66B | 16.13B | 16.38B | 15.86B |
| Total Debt | 8.96B | 8.96B | 8.95B | 8.97B | 8.00B | 7.62B | 7.61B | 7.61B | 7.60B | 6.14B | 6.14B | 6.13B |
| Cash & Equiv | 812.00M | 586.39M | 619.00M | 938.94M | 631.91M | 1.09B | 929.03M | 950.05M | 1.76B | 843.00M | 477.01M | 936.45M |
| Book Value | 6.83B | 6.89B | 6.48B | 6.41B | 6.35B | 6.69B | 6.95B | 6.87B | 6.48B | 6.50B | 6.53B | 6.14B |
| Return on Equity | 0.00 | 0.04 | 0.03 | 0.04 | 0.00 | 0.04 | 0.03 | 0.08 | 0.02 | 0.00 | 0.08 | 0.01 |
RPRX News
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Royalty Pharma Q2 Earnings Call Highlights
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma reports second quarter 2026 results